We are analyzing https://link.springer.com/article/10.1007/s10549-017-4294-5.

Title:
High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers | Breast Cancer Research and Treatment
Description:
Cyclin D1 has a central role in cell cycle control and is an important component of estrogen regulation of cell cycle progression. We have previously shown that high cyclin D expression is related to aggressive features of ER-positive but not ER-negative breast cancer. The aims of the present study were to validate this differential ER-related effect and furthermore explore the relationship between cyclin D overexpression and CCND1 gene amplification status in a node-negative breast cancer case–control study. Immunohistochemical nuclear expression of cyclin D1 (n = 364) and amplification of the gene CCND1 by fluorescent in situ hybridization (n = 255) was performed on tissue microarray sections from patients with T1-2N0M0 breast cancer. Patients given adjuvant chemotherapy were excluded. The primary event was defined as breast cancer death. Breast cancer-specific survival was analyzed in univariate and multivariable models using conditional logistic regression. Expression of cyclin D1 above the median (61.7%) in ER breast cancer was associated with an increased risk for breast cancer death (OR 3.2 95% CI 1.5–6.8) also when adjusted for tumor size and grade (OR 3.1). No significant prognostic impact of cyclin D1 expression was found among ER-negative cases. Cyclin D1 overexpression was significantly associated to high expression of the proliferation markers cyclins A (ρ 0.19, p = 0.006) and B (ρ 0.18, p = 0.003) in ER-positive tumors, but not in ER-negative cases. There was a significant association between CCND1 amplification and cyclin D1 expression (p = 0.003), but CCND1 amplification was not statistically significantly prognostic (HR 1.4, 95% CI 0.4–4.4). We confirmed our previous observation that high cyclin D1 expression is associated to high proliferation and a threefold higher risk of death from breast cancer in ER-positive breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Photography

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cyclin, cancer, breast, expression, pubmed, google, scholar, article, prognostic, cas, high, amplification, erpositive, study, ccnd, cases, patients, ernegative, gene, association, studies, prognosis, res, proliferation, overexpression, tumors, adjuvant, impact, tumor, significant, central, receptor, cell, found, table, oncol, analysis, estrogen, effect, status, results, previous, tamoxifen, significantly, correlation, transatac, treatment, chemotherapy, markers, carcinoma,

Topics {✒️}

population-based case-control study er-positive cell lines er-negative breast cancers er-positive breast cancers article download pdf tris–edta ph9 buffer node-negative breast cancer t1-2n0m0 breast cancer reis-filho js cell cycle control cell cycle activation orange-labeled ccnd1-specific activated cell cycle er-negative breast cancer er-positive breast cancer erbb2-positive breast cancer 4-μm-thick tma sections cell cycle progression er receptor-positive disease invasive breast cancers breast cancer-specific survival recipient paraffin blocks shorter metastasis-free survival er-negative cases separately advanced breast cancer karin jirström differential er-related effect er-negative cancers lymph node metastasis hormone-receptor-positive human breast cancer automated image analysis luminal breast cancer method standardization cut-offs lymph node involvement lymph node metastases early breast cancer postmenopausal breast cancer full access dual-probe kit privacy choices/manage cookies cell cycle 12 invasive breast cancer estrogen receptor status elin embretsén-varro finn rs de jong js human breast carcinomas invasive breast carcinoma breast cancer mortality

Questions {❓}

Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, Larsimont D, Piccart M (2003) Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
         description:Cyclin D1 has a central role in cell cycle control and is an important component of estrogen regulation of cell cycle progression. We have previously shown that high cyclin D expression is related to aggressive features of ER-positive but not ER-negative breast cancer. The aims of the present study were to validate this differential ER-related effect and furthermore explore the relationship between cyclin D overexpression and CCND1 gene amplification status in a node-negative breast cancer case–control study. Immunohistochemical nuclear expression of cyclin D1 (n = 364) and amplification of the gene CCND1 by fluorescent in situ hybridization (n = 255) was performed on tissue microarray sections from patients with T1-2N0M0 breast cancer. Patients given adjuvant chemotherapy were excluded. The primary event was defined as breast cancer death. Breast cancer-specific survival was analyzed in univariate and multivariable models using conditional logistic regression. Expression of cyclin D1 above the median (61.7%) in ER breast cancer was associated with an increased risk for breast cancer death (OR 3.2 95% CI 1.5–6.8) also when adjusted for tumor size and grade (OR 3.1). No significant prognostic impact of cyclin D1 expression was found among ER-negative cases. Cyclin D1 overexpression was significantly associated to high expression of the proliferation markers cyclins A (ρ 0.19, p = 0.006) and B (ρ 0.18, p = 0.003) in ER-positive tumors, but not in ER-negative cases. There was a significant association between CCND1 amplification and cyclin D1 expression (p = 0.003), but CCND1 amplification was not statistically significantly prognostic (HR 1.4, 95% CI 0.4–4.4). We confirmed our previous observation that high cyclin D1 expression is associated to high proliferation and a threefold higher risk of death from breast cancer in ER-positive breast cancer.
         datePublished:2017-05-20T00:00:00Z
         dateModified:2017-05-20T00:00:00Z
         pageStart:667
         pageEnd:678
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s10549-017-4294-5
         keywords:
            Breast cancer
            Proliferation
            Cyclin D1
            CCND1
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-017-4294-5/MediaObjects/10549_2017_4294_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-017-4294-5/MediaObjects/10549_2017_4294_Fig2_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:164
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Cecilia Ahlin
               affiliation:
                     name:Örebro University
                     address:
                        name:Department of Oncology, Örebro University, Örebro, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Claudia Lundgren
               url:http://orcid.org/0000-0002-7895-7844
               affiliation:
                     name:Uppsala University
                     address:
                        name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Elin Embretsén-Varro
               affiliation:
                     name:Örebro University
                     address:
                        name:Department of Oncology, Örebro University, Örebro, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Karin Jirström
               affiliation:
                     name:Department of Oncology and Pathology Lund University
                     address:
                        name:Department of Oncology and Pathology Lund University, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Carl Blomqvist
               affiliation:
                     name:Örebro University
                     address:
                        name:Department of Oncology, Örebro University, Örebro, Sweden
                        type:PostalAddress
                     type:Organization
                     name:Helsinki University
                     address:
                        name:Department of Oncology, Helsinki University, Helsinki, Finland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. -L. Fjällskog
               affiliation:
                     name:Uppsala University
                     address:
                        name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
      description:Cyclin D1 has a central role in cell cycle control and is an important component of estrogen regulation of cell cycle progression. We have previously shown that high cyclin D expression is related to aggressive features of ER-positive but not ER-negative breast cancer. The aims of the present study were to validate this differential ER-related effect and furthermore explore the relationship between cyclin D overexpression and CCND1 gene amplification status in a node-negative breast cancer case–control study. Immunohistochemical nuclear expression of cyclin D1 (n = 364) and amplification of the gene CCND1 by fluorescent in situ hybridization (n = 255) was performed on tissue microarray sections from patients with T1-2N0M0 breast cancer. Patients given adjuvant chemotherapy were excluded. The primary event was defined as breast cancer death. Breast cancer-specific survival was analyzed in univariate and multivariable models using conditional logistic regression. Expression of cyclin D1 above the median (61.7%) in ER breast cancer was associated with an increased risk for breast cancer death (OR 3.2 95% CI 1.5–6.8) also when adjusted for tumor size and grade (OR 3.1). No significant prognostic impact of cyclin D1 expression was found among ER-negative cases. Cyclin D1 overexpression was significantly associated to high expression of the proliferation markers cyclins A (ρ 0.19, p = 0.006) and B (ρ 0.18, p = 0.003) in ER-positive tumors, but not in ER-negative cases. There was a significant association between CCND1 amplification and cyclin D1 expression (p = 0.003), but CCND1 amplification was not statistically significantly prognostic (HR 1.4, 95% CI 0.4–4.4). We confirmed our previous observation that high cyclin D1 expression is associated to high proliferation and a threefold higher risk of death from breast cancer in ER-positive breast cancer.
      datePublished:2017-05-20T00:00:00Z
      dateModified:2017-05-20T00:00:00Z
      pageStart:667
      pageEnd:678
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s10549-017-4294-5
      keywords:
         Breast cancer
         Proliferation
         Cyclin D1
         CCND1
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-017-4294-5/MediaObjects/10549_2017_4294_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-017-4294-5/MediaObjects/10549_2017_4294_Fig2_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:164
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Cecilia Ahlin
            affiliation:
                  name:Örebro University
                  address:
                     name:Department of Oncology, Örebro University, Örebro, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Claudia Lundgren
            url:http://orcid.org/0000-0002-7895-7844
            affiliation:
                  name:Uppsala University
                  address:
                     name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Elin Embretsén-Varro
            affiliation:
                  name:Örebro University
                  address:
                     name:Department of Oncology, Örebro University, Örebro, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Karin Jirström
            affiliation:
                  name:Department of Oncology and Pathology Lund University
                  address:
                     name:Department of Oncology and Pathology Lund University, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Carl Blomqvist
            affiliation:
                  name:Örebro University
                  address:
                     name:Department of Oncology, Örebro University, Örebro, Sweden
                     type:PostalAddress
                  type:Organization
                  name:Helsinki University
                  address:
                     name:Department of Oncology, Helsinki University, Helsinki, Finland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. -L. Fjällskog
            affiliation:
                  name:Uppsala University
                  address:
                     name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:164
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Örebro University
      address:
         name:Department of Oncology, Örebro University, Örebro, Sweden
         type:PostalAddress
      name:Uppsala University
      address:
         name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
         type:PostalAddress
      name:Örebro University
      address:
         name:Department of Oncology, Örebro University, Örebro, Sweden
         type:PostalAddress
      name:Department of Oncology and Pathology Lund University
      address:
         name:Department of Oncology and Pathology Lund University, Lund, Sweden
         type:PostalAddress
      name:Örebro University
      address:
         name:Department of Oncology, Örebro University, Örebro, Sweden
         type:PostalAddress
      name:Helsinki University
      address:
         name:Department of Oncology, Helsinki University, Helsinki, Finland
         type:PostalAddress
      name:Uppsala University
      address:
         name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Cecilia Ahlin
      affiliation:
            name:Örebro University
            address:
               name:Department of Oncology, Örebro University, Örebro, Sweden
               type:PostalAddress
            type:Organization
      name:Claudia Lundgren
      url:http://orcid.org/0000-0002-7895-7844
      affiliation:
            name:Uppsala University
            address:
               name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Elin Embretsén-Varro
      affiliation:
            name:Örebro University
            address:
               name:Department of Oncology, Örebro University, Örebro, Sweden
               type:PostalAddress
            type:Organization
      name:Karin Jirström
      affiliation:
            name:Department of Oncology and Pathology Lund University
            address:
               name:Department of Oncology and Pathology Lund University, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:Carl Blomqvist
      affiliation:
            name:Örebro University
            address:
               name:Department of Oncology, Örebro University, Örebro, Sweden
               type:PostalAddress
            type:Organization
            name:Helsinki University
            address:
               name:Department of Oncology, Helsinki University, Helsinki, Finland
               type:PostalAddress
            type:Organization
      name:M. -L. Fjällskog
      affiliation:
            name:Uppsala University
            address:
               name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Oncology, Örebro University, Örebro, Sweden
      name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden
      name:Department of Oncology, Örebro University, Örebro, Sweden
      name:Department of Oncology and Pathology Lund University, Lund, Sweden
      name:Department of Oncology, Örebro University, Örebro, Sweden
      name:Department of Oncology, Helsinki University, Helsinki, Finland
      name:Department of Immunology Genetics and Pathology (IGP), Uppsala University, Uppsala, Sweden

External Links {🔗}(273)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.45s.

LINK . SPRINGER . COM {}